Nonspecific analgesics, combination analgesics, and antiemetics
Copyright © 2024 Elsevier B.V. All rights reserved, including those for text and data mining, AI training, and similar technologies..
The acute treatment of migraine attacks should provide rapid, effective, and long-lasting symptom relief, causing minimal adverse effects. For this purpose, there are several specific and nonspecific acute treatments. In this chapter, we focus on molecules not specifically designed for migraines, including anti-inflammatory not specific analgesics, such as acetaminophen, acetylsalicylic acid, and other non-steroidal anti-inflammatory drugs (or COX-2 inhibitors); antinausea medications like metoclopramide or prochlorperazine, which can alleviate sickness and vomiting associated with migraines, and may also have a direct painkiller effect; combinations of simple analgesics or association of a painkiller with caffeine. This stimulant can help enhance the pain-relieving effects of some headache medications and provide its own analgesic effect; physical approaches: applying cold packs or heating pads on the forehead or neck, can help relieve migraine pain; other classes with limited to no evidence to support their use, such as intravenous corticosteroids or antiepileptic drugs as sodium valproate. Finally, we will briefly mention opioids, barbiturates, or medical cannabis, bearing in mind that their use is not recommended by current guidelines.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:199 |
---|---|
Enthalten in: |
Handbook of clinical neurology - 199(2024) vom: 02., Seite 3-16 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Martinelli, Daniele [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 05.02.2024 Date Revised 05.02.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1016/B978-0-12-823357-3.00035-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367970295 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367970295 | ||
003 | DE-627 | ||
005 | 20240205232141.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240203s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/B978-0-12-823357-3.00035-5 |2 doi | |
028 | 5 | 2 | |a pubmed24n1281.xml |
035 | |a (DE-627)NLM367970295 | ||
035 | |a (NLM)38307653 | ||
035 | |a (PII)B978-0-12-823357-3.00035-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Martinelli, Daniele |e verfasserin |4 aut | |
245 | 1 | 0 | |a Nonspecific analgesics, combination analgesics, and antiemetics |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.02.2024 | ||
500 | |a Date Revised 05.02.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 Elsevier B.V. All rights reserved, including those for text and data mining, AI training, and similar technologies. | ||
520 | |a The acute treatment of migraine attacks should provide rapid, effective, and long-lasting symptom relief, causing minimal adverse effects. For this purpose, there are several specific and nonspecific acute treatments. In this chapter, we focus on molecules not specifically designed for migraines, including anti-inflammatory not specific analgesics, such as acetaminophen, acetylsalicylic acid, and other non-steroidal anti-inflammatory drugs (or COX-2 inhibitors); antinausea medications like metoclopramide or prochlorperazine, which can alleviate sickness and vomiting associated with migraines, and may also have a direct painkiller effect; combinations of simple analgesics or association of a painkiller with caffeine. This stimulant can help enhance the pain-relieving effects of some headache medications and provide its own analgesic effect; physical approaches: applying cold packs or heating pads on the forehead or neck, can help relieve migraine pain; other classes with limited to no evidence to support their use, such as intravenous corticosteroids or antiepileptic drugs as sodium valproate. Finally, we will briefly mention opioids, barbiturates, or medical cannabis, bearing in mind that their use is not recommended by current guidelines | ||
650 | 4 | |a Review | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Antiemetics | |
650 | 4 | |a Caffeine | |
650 | 4 | |a Combination analgesics | |
650 | 4 | |a NSAIDs | |
650 | 4 | |a Nonsteroidal anti-inflammatory drugs | |
650 | 7 | |a Antiemetics |2 NLM | |
650 | 7 | |a Analgesics |2 NLM | |
650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
650 | 7 | |a Analgesics, Opioid |2 NLM | |
700 | 1 | |a Pocora, Maria Magdalena |e verfasserin |4 aut | |
700 | 1 | |a Tassorelli, Cristina |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Handbook of clinical neurology |d 2003 |g 199(2024) vom: 02., Seite 3-16 |w (DE-627)NLM180945874 |x 0072-9752 |7 nnns |
773 | 1 | 8 | |g volume:199 |g year:2024 |g day:02 |g pages:3-16 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/B978-0-12-823357-3.00035-5 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 199 |j 2024 |b 02 |h 3-16 |